ACLARIS THERAPEUTICS, INC. (NASDAQ:ACRS) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

ACLARIS THERAPEUTICS, INC. (NASDAQ:ACRS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

On June7, 2018, Aclaris Therapeutics, Inc. (the “Company”) held its 2018 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2018.Of the 30,906,003shares outstanding as of the record date, 28,050,902 shares, or 90.76%, were present or represented by proxy at the Annual Meeting.Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

Proposal No. 1:Election of twonominees to serve as directors until the 2021 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:

Name

VotesFor

VotesWithheld

Christopher Molineaux

 20,633,234 4,780,034

Bryan Reasons

 25,344,199 69,069

Broker Non-Votes: 2,637,634.

All nominees were elected.

Proposal No. 2:Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2018. The votes were cast as follows:

VotesFor

VotesAgainst

Abstained

Ratification of appointment of PricewaterhouseCoopers LLP

 28,037,542 11,906 1,454


About ACLARIS THERAPEUTICS, INC. (NASDAQ:ACRS)

Aclaris Therapeutics, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK). It has completed approximately three Phase II clinical trials of A-101. It has initiated over two multi-center, double blind Phase III clinical trials and an open label Phase III clinical trial of A-101 in patients with SK. It also intends to develop A-101 as a prescription treatment for common warts, also known as verruca vulgaris, and A-102, a gel dosage form of hydrogen peroxide, as a prescription treatment for SK and common warts. It has initiated a Phase II clinical trial to evaluate A-101 for the treatment of common warts.